C. Michael Pine's Insider Trades & SAST Disclosures
C. Michael Pine's most recent trade in EyePoint Pharmaceuticals Inc was a trade of 42,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 5, 2024.
Add Superstar Alert
Note
This is a custom search result for pattern C. Michael Pine.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
EyePoint Pharmaceuticals Inc
|
Pine C. Michael | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
C. Michael Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 21,000 | 21,000 | - | - | Restricted Stock Units | |
|
EyePoint Pharmaceuticals Inc
|
Pine C. Michael | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 30,570 | - | - | Restricted Stock Units | |
|
EyePoint Pharmaceuticals Inc
|
C. Michael Pine | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 19,628 (0%) | 0% | 0 | Common Stock | |
|
EyePoint Pharmaceuticals Inc
|
Pine C. Michael | Chief Corp Dev.&Strat. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 5,966 | 13,662 (0%) | 0% | 20.4 | 121,706 | Common Stock |
|
EyePoint Pharmaceuticals Inc
|
Pine Michael C. | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2023 | 45,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
C. Pine Michael | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 04 Dec 2023 | 45,000 | 50,343 (0%) | 0% | 12.6 | 567,900 | Common Stock |
|
EyePoint Pharmaceuticals Inc
|
Michael C. Pine | Chief Corp Dev.&Strat. Officer | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 04 Dec 2023 | 45,000 | 5,343 (0%) | 0% | 22 | 990,000 | Common Stock |
|
EyePoint Pharmaceuticals Inc
|
C. Michael Pine | Chief Corp Dev.&Strat. Officer | Sale of securities on an exchange or to another person at price $ 20.79 per share. | 04 Dec 2023 | 1,000 | 4,343 (0%) | 0% | 20.8 | 20,790 | Common Stock |
|
EyePoint Pharmaceuticals Inc
|
Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 45,855 | 45,855 | - | - | Restricted Stock Units | |
|
EyePoint Pharmaceuticals Inc
|
Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
|
EyePoint Pharmaceuticals Inc
|
Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 91,655 | 91,655 | - | - | Stock Option (Right to Buy) | |
|
EyePoint Pharmaceuticals Inc
|
Michael C. Pine | Chief Corp Dev.&Strat. Officer | Purchase of securities on an exchange or from another person at price $ 12.21 per share. | 14 Mar 2022 | 1,000 | 1,000 (0%) | 0% | 12.2 | 12,210 | Common Stock |
|
EyePoint Pharmaceuticals Inc
|
Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges